Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study.

Akkara Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Crowson CS.

J Rheumatol. 2013 Jul;40(7):1082-8. doi: 10.3899/jrheum.121302. Epub 2013 May 1.

2.

Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Curtis JR, John A, Baser O.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91. doi: 10.1002/acr.21693.

3.

Impact of statin use on lipid levels in statin-naive patients with rheumatoid arthritis versus non-rheumatoid arthritis subjects: results from a population-based study.

Myasoedova E, Gabriel SE, Green AB, Matteson EL, Crowson CS.

Arthritis Care Res (Hoboken). 2013 Oct;65(10):1592-9. doi: 10.1002/acr.22029.

4.

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease.

Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, Gabriel SE.

Ann Rheum Dis. 2011 Mar;70(3):482-7. doi: 10.1136/ard.2010.135871. Epub 2011 Jan 7.

5.

[Prevalence of dyslipidemia and elevated cardiovascular risk in patients with rheumatoid arthritis].

Haye Salinas MJ, Bertoli AM, Lema L, Saucedo C, Rosa J, Quintana R, Bellomio V, Aguero S, Spindler W, Tamborenea MN, Schimid M, Ceccato F, Sala JP, Paira S, Spindler A, Soriano ER, Estel BA, Caeiro F, Alvarellos A, Saurit V.

Medicina (B Aires). 2013;73(1):26-30. Spanish.

6.

Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.

Mehta S, Wells S, Grey C, Riddell T, Kerr A, Marshall R, Ameratunga S, Harrison J, Kenealy T, Bramley D, Chan WC, Thornley S, Sundborn G, Jackson R.

Eur J Prev Cardiol. 2014 Feb;21(2):192-202. doi: 10.1177/2047487312462150. Epub 2012 Oct 2.

PMID:
23033546
7.

Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population.

Liao KP, Cai T, Gainer VS, Cagan A, Murphy SN, Liu C, Churchill S, Shaw SY, Kohane I, Solomon DH, Plenge RM, Karlson EW.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):2046-50. doi: 10.1002/acr.22091.

8.

Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.

Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE.

Arthritis Rheum. 2004 Nov;50(11):3450-7.

9.

Cardiovascular risk factor management in patients with RA compared to matched non-RA patients.

Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Mölken MP, Liao KP, Solomon DH.

Rheumatology (Oxford). 2016 May;55(5):809-16. doi: 10.1093/rheumatology/kev427. Epub 2015 Dec 24.

10.

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O'Fallon WM, Gabriel SE.

Ann Rheum Dis. 2008 Jan;67(1):64-9. Epub 2007 May 21.

PMID:
17517756
11.

Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.

Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, Caplan L, Michaud K, Mikuls T.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1619-26. doi: 10.1002/acr.22341.

12.

Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.

García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X.

J Rheumatol. 2009 Jul;36(7):1365-70. doi: 10.3899/jrheum.080928. Epub 2009 Apr 15.

PMID:
19369465
13.

Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic.

Rollefstad S, Kvien TK, Holme I, Eirheim AS, Pedersen TR, Semb AG.

Ann Rheum Dis. 2013 Dec;72(12):1968-74. doi: 10.1136/annrheumdis-2012-202789. Epub 2012 Dec 22.

PMID:
23264359
14.

Mortality trends in rheumatoid arthritis: the role of rheumatoid factor.

Gonzalez A, Icen M, Kremers HM, Crowson CS, Davis JM 3rd, Therneau TM, Roger VL, Gabriel SE.

J Rheumatol. 2008 Jun;35(6):1009-14. Epub 2008 Apr 15.

15.

The association between the receipt of lipid lowering therapy and HIV status among veterans who met NCEP/ATP III criteria for the receipt of lipid lowering medication.

Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC.

J Gen Intern Med. 2009 Mar;24(3):334-40. doi: 10.1007/s11606-008-0891-7. Epub 2009 Jan 6.

16.

Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery.

Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM.

JAMA. 2004 May 5;291(17):2092-9.

PMID:
15126437
17.

Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting.

Jafri K, Taylor L, Nezamzadeh M, Baker JF, Mehta NN, Bartels C, Williams CT, Ogdie A.

BMC Musculoskelet Disord. 2015 Sep 3;16:237. doi: 10.1186/s12891-015-0700-5.

18.
19.

Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis.

Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):362-70. doi: 10.1002/acr.20105.

20.

Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis.

Tournadre A, Tatar Z, Pereira B, Chevreau M, Gossec L, Gaudin P, Soubrier M, Dougados M.

Int J Cardiol. 2015 Mar 15;183:149-54. doi: 10.1016/j.ijcard.2015.01.069. Epub 2015 Jan 28.

Supplemental Content

Support Center